Hubei Biocause Heilen Pharmaceutical Resultados de beneficios anteriores
Pasado controles de criterios 1/6
Hubei Biocause Heilen Pharmaceutical has been growing earnings at an average annual rate of 3.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 1.3% per year. Hubei Biocause Heilen Pharmaceutical's return on equity is 4.6%, and it has net margins of 23.4%.
Información clave
3.9%
Tasa de crecimiento de los beneficios
-5.3%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 10.9% |
| Tasa de crecimiento de los ingresos | -1.3% |
| Rentabilidad financiera | 4.6% |
| Margen neto | 23.4% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings
Nov 04
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Recent updates
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings
Nov 04Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%
Oct 30Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)
Aug 07Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Desglose de ingresos y gastos
Cómo gana y gasta dinero Hubei Biocause Heilen Pharmaceutical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 455 | 106 | 55 | 44 |
| 30 Jun 24 | 499 | 132 | 59 | 52 |
| 31 Mar 24 | 608 | 174 | 61 | 57 |
| 31 Dec 23 | 663 | 176 | 61 | 53 |
| 30 Sep 23 | 712 | 192 | 49 | 40 |
| 30 Jun 23 | 680 | 184 | 53 | 30 |
| 31 Mar 23 | 580 | 138 | 45 | 22 |
| 01 Jan 23 | 515 | 126 | 46 | 20 |
| 30 Sep 22 | 468 | 101 | 56 | 21 |
| 30 Jun 22 | 504 | 108 | 44 | 20 |
| 31 Mar 22 | 548 | 113 | 44 | 20 |
| 01 Jan 22 | 541 | 122 | 40 | 18 |
| 30 Sep 21 | 589 | 138 | 49 | 23 |
| 30 Jun 21 | 576 | 144 | 51 | 25 |
| 31 Mar 21 | 567 | 159 | 63 | 23 |
| 31 Dec 20 | 593 | 168 | 68 | 23 |
| 31 Dec 19 | 660 | 100 | 93 | 25 |
| 31 Dec 18 | 517 | 48 | 83 | 21 |
| 31 Dec 17 | 366 | 10 | 46 | 18 |
Ingresos de calidad: 301211 has a high level of non-cash earnings.
Margen de beneficios creciente: 301211's current net profit margins (23.4%) are lower than last year (26.9%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 301211's earnings have grown by 3.9% per year over the past 5 years.
Acelerando crecimiento: 301211's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Beneficios vs. Industria: 301211 had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rentabilidad financiera
Alta ROE: 301211's Return on Equity (4.6%) is considered low.